Peptides in the Public Eye: What Celebrities, Influencers and Media Coverage Actually Said

Over the past few years, peptides have moved from a niche laboratory topic into mainstream entertainment, podcasting and social media, as recent reporting by The Independent and BBC News describes. This article summarizes what was publicly said and reported, with a source for each point, and what that coverage does and does not mean.

The celebrity wave

Much of the celebrity coverage concerned approved prescription medicines rather than research peptides. At the Academy Awards on 12 March 2023, host Jimmy Kimmel joked from the stage about a prescription weight-management medication, as Deadline reported. In October 2022, Elon Musk answered a question on Twitter (now X) about his appearance by naming fasting and a prescription weight-management medication, according to Fox Business. In December 2023, Oprah Winfrey told People that her doctor had prescribed a weight-management medication, which she chose not to name. These are stories about approved prescription drugs. They appear here only as context for how peptide-related topics reached mainstream audiences.

The podcast circuit

Joe Rogan has talked about BPC-157 on his podcast, The Joe Rogan Experience, as The Independent reported in November 2025. In June 2026, Andrew Huberman's Huberman Lab podcast published an episode on peptides with physician Abud Bakri. According to the episode page, the conversation covers the gap between animal and human data and the risks and uncertainties in the field.

Social media and the press

In a Q&A published by Harvard T.H. Chan School of Public Health on 1 October 2026, Professor S. Bryn Austin said that influencers are promoting synthetic peptides including BPC-157 and TB-500, and that many of them have undergone little to no rigorous clinical testing and have not been approved by the FDA. The Independent (November 2025) and BBC News (March 2026) both reported on grey-market peptides labelled "for research purposes only" being used by people, and quoted experts who said those people risk turning themselves into "lab rats".

What the coverage blurs

In our reading, much of this content collapses distinctions that matter to a laboratory: between approved drugs and research materials, between clinical trial data and anecdote, and between laboratory supply and personal use. Regulators have also responded publicly. In February 2026, the FDA announced that it intends to restrict ingredients used in non-FDA-approved compounded weight-management drugs that are mass-marketed to consumers, and to act against misleading marketing of those products.

Our position, stated plainly

BioLabs Research sells laboratory reagents for research use only. Nothing a celebrity, podcast host or influencer said about personal use applies to anything we sell, and we do not market to that audience. We publish this article because the public conversation is part of the reality our research customers operate in, and because understanding the difference between hype and documentation is exactly the skill a serious lab buyer needs.

Sources

• Deadline | 2023-03-12 | deadline.com
• Fox Business | 2022-10-14 | www.foxbusiness.com
• People | 2023-12-14 | people.com
• Huberman Lab (episode page) | 2026-06-01 | www.hubermanlab.com
• Harvard T.H. Chan School of Public Health | 2026-10-01 | hsph.harvard.edu
• The Independent | 2025-11-30 | www.independent.co.uk
• BBC News | 2026-03-01 | www.bbc.com
• U.S. FDA (press announcement) | 2026-02-06 | www.fda.gov

BioLabs Research has no affiliation with, and no endorsement from, any person named in this article.

This article is a summary of publicly reported information for research-community awareness only. It is not medical advice, not legal advice, and not a statement about any BioLabs Research product.

For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.

This summary is for research-community awareness only and is not legal advice.